Israel's trade commissioner named four Canadian cannabis producers for examination in an announcement of 22 October 2026, according to Canadian trade publication StratCann. The selection advances an inquiry into alleged dumping, meaning exports sold below their normal value, but the report did not identify a preliminary duty decision.1
The sample separates different production methods
The named businesses are GrowCo, Cielo Verde Quebec, 2323414 Alberta and Koots Canna. StratCann reports that the commissioner distinguished GrowCo's greenhouse operation from indoor producers and proposed examining it separately alongside a sample of premium suppliers. Officials said the selected businesses accounted for about 70% of Canadian cannabis exports to Israel.1
The commissioner invited written comments on the proposed sample during October. Naming these producers was a procedural step, rather than a finding that they had broken trade rules.1
Hebrew publication Cannna explains that reducing the number of producers examined individually does not necessarily narrow the products or transactions covered. A sample is a method for calculating findings, rather than an automatic exemption for exporters outside it. It also distinguishes an investigation from a final finding or an imposed levy.2
Israeli producers and importers dispute the case
Calcalist's account of the restarted inquiry says local producers complained that Canadian competition was damaging their businesses. The ministry defended its work as:
חקירה כלכלית מקצועית ועניינית
A professional, substantive economic investigation.3
The same report records opposition from import interests, which criticised the uncertainty created by repeated proceedings. It also describes concern from the Israel Cancer Association about prices and availability. These are arguments advanced by participants, rather than established consequences of a duty that has already taken effect.3
The Chambers of Commerce asked the Justice Ministry to intervene and freeze the inquiry pending legal examination of the commissioner's authority and the reasonableness of reopening proceedings.3
StratCann's earlier October report says Canadian producers denied the dumping allegations. It describes the August investigation as following previous attempts to secure duties which the finance minister had opposed. The dispute therefore concerns both the comparison of prices and the consequences of trade protection for competition in Israel's medical market.4
Canadian consultation does not settle Israel's investigation
On 31 October 2026, StratCann reported that Global Affairs Canada planned an industry meeting for 3 November. Its stated purpose was to hear exporters' concerns, consider next steps and discuss possible government support. The report announces a consultation, not an agreement with Israeli authorities.5
Cannna's subsequent explanation similarly cautions that a meeting cannot establish a change in import conditions or pharmacy prices. Any commercial effect depends on later official decisions and companies' responses. The accounts reviewed here do not establish the meeting's outcome or a subsequent final levy.2 5
The unresolved question is whether the commissioner publishes a determination explaining the accepted sample, the price comparisons and any proposed measure, together with the parties' responses.1 2